An NTP Affiliated Office-Based Opiate Treatment (OBOT) Program in a Public Health Setting
description
Transcript of An NTP Affiliated Office-Based Opiate Treatment (OBOT) Program in a Public Health Setting
An NTP Affiliated Office-Based Opiate Treatment (OBOT) Program
in a Public Health Setting
Alice Gleghorn, PhDAlice Gleghorn, PhDSFDPH OBOT DirectorSFDPH OBOT Director
2
Heroin in San Francisco 15,000-17,000 active heroin users (2001 HIV
Consensus Report)
2,663 methadone maintenance slots and 651 methadone detoxification slots (SF Methadone Clinic Phone Survey, 2003)
Most frequently mentioned drug involved in drug-related deaths (DAWN Report, 2002)
59% of IDUs would accept treatment (Urban Health Study, 2001)
3
Community costs of opiate dependence
Hospital charges for treatment of IVDU abscesses are at least $20 million per year (Masson et. al.)
Every $1 invested in treatment yields up to $7 in reduced crime-related costs (CalData study)
1/3 of treatment admissions list heroin addiction as the primary reason (CSAS database, 2003))
4
Why the Access Gap??
Inability to expand existing, or site new, methadone treatment facilities (Prop I)
Insufficient funding for indigent clients
Stigma/mythology/misinformation regarding methadone treatment
5
San Francisco Initiatives to Close the Access Gap (1998-Present)
Increased Funding for OAT /New InitiativesSan Francisco Department of Public Health
Expansion of MM slotsCreation of Integrated Soft Tissue Infection ClinicBuprenorphine Expansion
Federal Grants (with DPH back-fill)Action-Point (HIV) ProgramMethadone Van (Federal/DPH)Psychopharmacology Grant
OBOT (Federal/DPH)NIH-SPNS Grant for HIV/Buprenorphine
6
The San Francisco OBOT Pilot Program
1998- Board of Supervisors passes resolution directing DPH to:
“Allow physicians full discretion to treat opiate addiction through prescription methadone”
“Apply for any federal/state waivers that would allow for the development of an effective and safe program”
7
OBOT Working Group Development of policy and operations accomplished
by sub-committees including participation of: Narcotics Treatment Program (NTP) directors and
staff Primary care physicians Substance abuse counselors Pharmacists Consumers of treatment services City and County of San Francisco State and federal regulatory agencies (ADP, DEA,
CSAT)
8
OBOT San FranciscoProgram Planning
1998- DPH convenes interdisciplinary work group to produce a consensus statement
1999- Three subcommittees produce recommendations (provider, pharmacy, counselor)
2001- Grant application submitted to CSAT for pilot OBOAT program
2002- OBOT license application submitted to CSAT, ADP, DEA
2003- OBOT Pilot approved by CSAT, ADP, DEA
9
OBOT Guiding Principles
Expand access to effective treatment
Increase patient choice
Integrate care
Reduce stigma
Regulatory Parity for NTPs
10
San Francisco OBOT-related Legislation
Board of Supervisors Resolution - 1997
California SB 1807 - 2000
Drug Abuse Treatment Act - 2000
CSAT Buprenorphine Approval - 2002
11
San Francisco OBOT Program Framework
Central administration Multiple patient access points Treatment team and individualized
treatment plans Training and certification for all staff Ongoing evaluation and quality
assurance
12
SFDPH OBOT Program Status
Operates as CA Pilot OBOT of SB1807 Has specific state-approved exceptions to
Title 9 Was developed to be consistent with federal
guidelines for office-based practice Was implemented in partnership with ADP Is licensed as an OBOT “affiliated” with SFGH
Ward 93 NTP
13
San Francisco OBOT Timeline CSAT Approval May 2003
DADP OBOT License May 2003
Patient enrollment begins Dr. Leavitt July 2003 Tom Waddell HC Sept. 2003 Potrero Hill HC Oct. 2003 BAART Hyde St. Clinic Dec. 2003 Jail Health Svcs. Feb. 2004
14
OBOT Pharmacies
San Francisco General Hospital Pharmacy Mission District Provide methadone dispensing to 45 OBOT clients
Community Behavioral Health Services Pharmacy South of Market Area Provide buprenorphine dispensing to 55 OBOT
clients OBOT Buprenorphine Induction Clinic (OBIC)
Mission District Induce/stabilize up to 55 OBOT-buprenorphine
patients
15
Potrero Hill Health Center
Patient capacity=30
16
Tom Waddell Health Center
Patient capacity=30
17
Quality Control:Centralized Information System
A secured Internet-accessible data base is used by primary care providers, counselors, pharmacists, and administrators
Creates electronic chart on patient characteristics, treatment plans, use of treatment services, and lab results
Medication orders are transmitted by physician to pharmacy
Patients visit pharmacy for observed dosing and take-home dosing
Pharmacists record daily dosing Facilitates quality assurance activities
18
Password-protected Online Patient Record
19
Patient Enrollment Folder
20
Quality Assurance
Staff training (didactic / practicum/ database/ logistics)
Weekly cross-site and on-site clinical review/supervision
Monthly counselor training Weekly core, monthly cross-site
implementation meeting Database monitoring for clinical, state and
Federal guideline adherence; monthly report to all providers
21
Patient Treatment Folder
22
Evaluation Goals Document recruitment and patient demographics Evaluate compliance with / retention in treatment Evaluate impact on drug and alcohol use Evaluate impact on other indicators (medical, psychiatric,
employment, psychosocial functioning) Evaluated impact on utilization of medical, psychiatric,
forensic, and other city services (cost analysis) Identify predictors of success Solicit patient and provider satisfaction/feedback Compare outcomes with traditional methadone clinics Begin to assess aspects of treatment with buprenorphine
23
Demographics of OBOT Patients (N=80)
Methadone TrackMethadone Track 48 total enrolled in
stabilization or community 2 left community
treatment 36 enrolled in
community• 74% male• 12% homeless• Mean LOS 233
(52-428) 2 currently in stabilization 8 left stabilization
BuprenorphineBuprenorphine Track Track 32 total enrolled32 total enrolled
59% male59% male 31% homeless31% homeless Mean LOS 124.5 Mean LOS 124.5
(1-361)(1-361) 8 dropped out (5/8 JHS)8 dropped out (5/8 JHS) 24 currently enrolled24 currently enrolled
Mean LOS 157 Mean LOS 157 (32-361)(32-361)
24
Preliminary Conclusions from OBOT Pilot Site Staffing key to implementation Site Staffing key to implementation Site Logistics determine barriersSite Logistics determine barriers Jail-to-community transition difficultJail-to-community transition difficult Counselor and pharmacist play larger, on-Counselor and pharmacist play larger, on-
going role in treatmentgoing role in treatment Central administration necessary for Central administration necessary for
regulatory and management issuesregulatory and management issues Evidence supporting OBOT in PC, NTP Evidence supporting OBOT in PC, NTP
satellite and Addiction Specialty settingssatellite and Addiction Specialty settings
The San Francisco Office Based Opiate Addiction Treatment (OBOT)
Pilot ProjectClinical Corner Stones
David Hersh, MDProgram Philosophy/Guiding Principals
Federal and State RegulationsOBOT-Pilot Practice Guidelines
Program StructureThe Patients and the Providers
Staff TrainingContinuous Quality Improvement
Program Evaluation
26
27
Opiate dependence is a medical condition Opiate agonist treatment is provided in the community
as part of the patient’s overall medical care Treatment is individualized and patient-centered The physician, counselor, and pharmacist work closely
to coordinate patient care No prior OAT treatment required for admission Observed dosing, urine toxicology screening, and
counseling are critical aspects of care Access to higher level of care (e.g., initial stabilization
and “safety net”) is critical
The San Francisco OBOT PilotGuiding Principals
28
The San Francisco OBOT PilotClinical Considerations
Federal and State Regulations
Code of Federal Regulations- 42 CFRCode of Federal Regulations- 42 CFR““Opioid Drugs in Maintenance and Opioid Drugs in Maintenance and
Detoxification Treatment of Opiate Detoxification Treatment of Opiate Addiction”Addiction”
California Code of Regulations- Title 9California Code of Regulations- Title 9““Narcotic Treatment Programs”Narcotic Treatment Programs”
29
Methadone or buprenorphine can be utilized “Stabilization and Evaluation” tracks available at affiliated
NTP/intensive buprenorphine program prior to transfer to the community or if deteriorating in the program
Medication Take-HomesMedication Take-Homes MethadoneMethadone- Step levels as per Federal Regs.- Step levels as per Federal Regs. BuprenorphineBuprenorphine- As per OBOT Clinical Guidelines- As per OBOT Clinical Guidelines
Toxicology ScreensToxicology Screens- - At least 8xs/yearAt least 8xs/year CounselingCounseling- - At least 50 minutes/monthAt least 50 minutes/month Medication OrdersMedication Orders- Transmitted electronically to - Transmitted electronically to
pharmacy through OBOT databasepharmacy through OBOT database
The San Francisco OBOT PilotSome Basic Clinical Elements
30
The San Francisco Office Based Opiate Addiction Treatment (OBOT) Pilot Project
Programmatic Components
Two Community Primary Care Health Centers Two Community Primary Care Health Centers (75 patients- 30 methadone/45 buprenorphine)(75 patients- 30 methadone/45 buprenorphine)
NTP Satellite Clinic NTP Satellite Clinic (10 methadone patients)(10 methadone patients)
Private Practitioner’s Office (addiction/psychiatry)Private Practitioner’s Office (addiction/psychiatry)(5 patients- methadone or buprenorphine)(5 patients- methadone or buprenorphine)
Affiliated NTP (OTOP- “Stabilization and Evaluation” Affiliated NTP (OTOP- “Stabilization and Evaluation” Track)Track)
OBOT Buprenorphine Induction Clinic (OBIC)OBOT Buprenorphine Induction Clinic (OBIC) Two Community PharmaciesTwo Community Pharmacies
31
The San Francisco Office Based Opiate Addiction Treatment (OBOT) Pilot Project
The Human Element
The PatientsThe Patients The ProvidersThe Providers
The OBOT PhysicianThe OBOT PhysicianThe OBOT CounselorThe OBOT CounselorThe OBOT PharmacistThe OBOT Pharmacist
The OBOT Quality The OBOT Quality Assurance/Evaluation TeamAssurance/Evaluation Team
32
The OBOT Patient Inclusion/Exclusion Criteria
At least 18 years oldAt least 18 years old San Francisco residentSan Francisco resident Opiate dependent (at least 1 year)Opiate dependent (at least 1 year) No active, uncontrolled, serious medical, psychiatric, or behavioral conditionNo active, uncontrolled, serious medical, psychiatric, or behavioral condition Willingness to continue in OAT for at least one yearWillingness to continue in OAT for at least one year Anticipated ability to comply with OBOT expectations and do well at the Anticipated ability to comply with OBOT expectations and do well at the
level of care provided through OBOTlevel of care provided through OBOT No abuse or dependence on alcohol or sedative hypnoticsNo abuse or dependence on alcohol or sedative hypnotics Not pregnant or planning to become pregnantNot pregnant or planning to become pregnant Willingness to use adequate birth controlWillingness to use adequate birth control Specifically for buprenorphine Specifically for buprenorphine
No acute/chronic pain syndrome requiring the use of narcotic analgesicsNo acute/chronic pain syndrome requiring the use of narcotic analgesics Not currently taking greater than 35 mgs of methadone dailyNot currently taking greater than 35 mgs of methadone daily
33
The San Francisco Office Based Opiate Addiction Treatment (OBOT) Pilot Project
OBOT Providers- Expectations and Responsibilities
Provide services at participating OBOT sitesProvide services at participating OBOT sites Posses required licenses/certificationsPosses required licenses/certifications Attend prerequisite trainingsAttend prerequisite trainings Provide adequate back-up capacity and Provide adequate back-up capacity and
referral servicesreferral services Willingness to comply with Federal, State, Willingness to comply with Federal, State,
and Pilot policies and proceduresand Pilot policies and procedures
34
The San Francisco Office Based Opiate Addiction Treatment (OBOT) Pilot Project
Provider Trainings
Prior to participationPrior to participation At least 8-hour didactic OBOT/Buprenorphine TrainingAt least 8-hour didactic OBOT/Buprenorphine Training Practicum experience at OTOPPracticum experience at OTOP On site general trainings (addiction/recovery, OAT etc)On site general trainings (addiction/recovery, OAT etc) Other required trainings:Other required trainings:
OBOT-specific clinical guidelines (includes review OBOT-specific clinical guidelines (includes review of pertinent Federal and State regulations)of pertinent Federal and State regulations)
ASI and treatment planningASI and treatment planning OBOT policies/proceduresOBOT policies/procedures Database trainingsDatabase trainings
35
The OBOT Pilot ProgramThe Treatment Process
I.I. Patient identificationPatient identificationII.II. Eligibility determinationEligibility determinationIII.III. Choosing a medicationChoosing a medicationIV.IV. ?Need for stabilization/evaluation prior to entry??Need for stabilization/evaluation prior to entry?V.V. Transfer to community site/pharmacyTransfer to community site/pharmacyVI.VI. Ongoing assessment of clinical courseOngoing assessment of clinical course
I.I. Need for additional services?Need for additional services?II.II. Need for re-stabilization at any point?Need for re-stabilization at any point?III.III. Need for transfer to other level of care?Need for transfer to other level of care?
36
The Affiliated NTPRoles and Responsibilities
Program DevelopmentProgram Development Provider TrainingProvider Training Stabilization and Evaluation TrackStabilization and Evaluation Track
Prior to entryPrior to entry Safety netSafety net
Ongoing ConsultationOngoing Consultation
37
The Affiliated NTPThe Stabilization and Evaluation
Track Two-to-four month maintenance track to evaluate Two-to-four month maintenance track to evaluate
appropriateness for OBOT appropriateness for OBOT Stabilization of methadone doseStabilization of methadone dose Frequent counseling and toxicology screensFrequent counseling and toxicology screens Assess (address if possible) for acute medical, Assess (address if possible) for acute medical,
psychiatric, behavioral, or psychosocial problemspsychiatric, behavioral, or psychosocial problems Remain in close communication with referring siteRemain in close communication with referring site Facilitate transfer to OBOT or to other level of care as Facilitate transfer to OBOT or to other level of care as
appropriateappropriate
38
The OBOT Buprenorphine Induction Clinic (OBIC)
Roles and Responsibilities
Stabilization and EvaluationStabilization and Evaluation Prior to transfer to communityPrior to transfer to community As a safety netAs a safety net
Provider TrainingProvider Training ConsultationConsultation
39
The OBOT DATABASE
A novel, password-protected database which links the physician,counselor and pharmacist
• Allows for electronic transmission of medication orders
• Creates an electronic chart (patient information, clinician notes, lab results etc)
• Facilitates quality assurance activities
40
THE SAN FRANCISCO OBOT PILOT
Continuous Quality Improvement Led by OBOT Clinical Coordinator and Medical DirectorLed by OBOT Clinical Coordinator and Medical Director Assisted by Core OBOT Team and affiliated NTPAssisted by Core OBOT Team and affiliated NTP Designated QA leader at each community treatment siteDesignated QA leader at each community treatment site Activities Include:
Staff training (didactic / practica) “Internal” Electronic and paper chart reviews Quarterly State audits Case conferences Warmline support OBOT Core (weekly), OBOT Admission (weekly), and
OBOT Implementation (monthly) mtgs
41
THE SAN FRANCISCO OBOT PILOT
Preliminary Data as of September 2004 Over 150 patients consideredOver 150 patients considered 70 patients enrolled70 patients enrolled 61 patients currently in treatment in community61 patients currently in treatment in community
36 methadone/25 buprenorphine36 methadone/25 buprenorphine 16/36 methadone patients from NTP stabilization, 20/36 16/36 methadone patients from NTP stabilization, 20/36
from maintenancefrom maintenance 24/25 buprenorphine patients induced at OBIC, 1/25 24/25 buprenorphine patients induced at OBIC, 1/25
induced in communityinduced in community 10 drop outs (9 buprenorphine*/1 methadone)10 drop outs (9 buprenorphine*/1 methadone)
*majority dropped out prior to or during “induction” at OBIC*majority dropped out prior to or during “induction” at OBIC
42
THE SAN FRANCISCO OBOT PILOT
Preliminary data as of June 2004 continued
Early ResultsEarly Results High compliance with treatmentHigh compliance with treatment Very few missed dosesVery few missed doses High program retentionHigh program retention Little-to-no clinical deterioration Little-to-no clinical deterioration Patients extremely satisfied with programPatients extremely satisfied with program Positive patient reports regarding Positive patient reports regarding
buprenorphinebuprenorphine
San Francisco CountyOBOT Pilot:
Pharmacy AspectsSharon Kotabe, PharmDSharon Kotabe, PharmDAssociate Administrator for Associate Administrator for
Pharmaceutical ServicesPharmaceutical ServicesAssociate Clinical Professor of Associate Clinical Professor of
Pharmacy, UCSFPharmacy, UCSF
44
In the beginning…… Pharmacy Subcommittee formed, November Pharmacy Subcommittee formed, November
19991999 Members representedMembers represented
County Health DepartmentCounty Health Department Local School of PharmacyLocal School of Pharmacy State Board of PharmacyState Board of Pharmacy State Poison Control SystemState Poison Control System Local chain, independent & hospital pharmaciesLocal chain, independent & hospital pharmacies Narcotic Treatment Programs (NTPs) and free Narcotic Treatment Programs (NTPs) and free
clinicsclinics
45
Pharmacy Subcommittee Charge
“ “ To develop and recommend a ‘best To develop and recommend a ‘best practices’ model to create medically practices’ model to create medically appropriate and geographically-appropriate and geographically-convenient dispensing of methadone in convenient dispensing of methadone in a PHARMACY-BASED SETTING in a PHARMACY-BASED SETTING in San Francisco”San Francisco”
46
Pharmacy Subcommittee Activities
Identified barriers to pharmacist participation Identified barriers to pharmacist participation in projectin project Pharmacists not included in “traditional” Pharmacists not included in “traditional”
maintenance program models and in maintenance program models and in California, restricted by law from dispensing California, restricted by law from dispensing maintenance opiates to known addictsmaintenance opiates to known addicts
Negative perceptions & beliefs re: addictionNegative perceptions & beliefs re: addiction Reimbursement for time necessary to Reimbursement for time necessary to
provide appropriate servicesprovide appropriate services
47
Pharmacy Subcommittee Activities
Identified benefits of pharmacist participation Identified benefits of pharmacist participation in programin program Expertise counseling patients on Expertise counseling patients on
medication and drug therapymedication and drug therapy Availability of patient’s entire drug profile Availability of patient’s entire drug profile
for drug-drug interaction and for drug-drug interaction and contraindication monitoringcontraindication monitoring
Increased access to treatment through Increased access to treatment through local “neighborhood” pharmacieslocal “neighborhood” pharmacies
48
Pharmacy Subcommittee Activities
Reviewed State and Federal regulations Reviewed State and Federal regulations for “traditional” narcotic treatment for “traditional” narcotic treatment programsprograms
Reviewed materials training materials Reviewed materials training materials used to educate pharmacy students used to educate pharmacy students about addiction and addiction about addiction and addiction pharmacology from various schools of pharmacology from various schools of pharmacy pharmacy
49
Pharmacy Subcommittee Activities
Met with pharmacists engaged in office-Met with pharmacists engaged in office-based treatment models in other Statesbased treatment models in other States
Matched zip-codes of clients already in Matched zip-codes of clients already in treatment with pharmacy locations to treatment with pharmacy locations to target potential dispensing pharmaciestarget potential dispensing pharmacies
Conducted focus groups with Conducted focus groups with pharmacists from 10 zip-codes with pharmacists from 10 zip-codes with highest number of current clientshighest number of current clients
50
Focus Group Comments
Support for expanding access to Support for expanding access to treatmenttreatment
Participation perceived as a natural Participation perceived as a natural expansion of professional role and expansion of professional role and responsibilities and welcomed challenge responsibilities and welcomed challenge of learning new skillsof learning new skills
Suggestions that program start slowly Suggestions that program start slowly with fewer initial clients, and for with fewer initial clients, and for scheduled “appointment times”scheduled “appointment times”
51
Pharmacy Subcommittee Recommendations (February 2001)
TrainingTraining Integrate with training for physicians, Integrate with training for physicians,
counselors and others to foster counselors and others to foster collaborative, team-approach to carecollaborative, team-approach to care
Focus on: (1) “mechanics” of Focus on: (1) “mechanics” of maintenance treatment and, (2) maintenance treatment and, (2) “raising consciousness” on nature of “raising consciousness” on nature of addictionaddiction
52
Recommendations (continued)…
Create central database for ready Create central database for ready access to relevant client information and access to relevant client information and recording dose administrationrecording dose administration
Allow pharmacies to establish dosing Allow pharmacies to establish dosing “appointments” as dictated by workload“appointments” as dictated by workload
Require establishment of dosing areas Require establishment of dosing areas separate and private from main separate and private from main pharmacy counseling windows pharmacy counseling windows
53
Recommendations (continued)…
Provide adequate securityProvide adequate security Provide access to “on-call” system to Provide access to “on-call” system to
advise pharmacists dealing with advise pharmacists dealing with complex client issuescomplex client issues
Pharmacists provide medication Pharmacists provide medication counseling, counselors and physicians counseling, counselors and physicians provide drug abuse counselingprovide drug abuse counseling
Provide adequate remunerationProvide adequate remuneration
54
….. and at last!
First patient enrolled, July 2003First patient enrolled, July 2003 Community pharmacy participationCommunity pharmacy participation
Corporate vs. individual pharmacist viewsCorporate vs. individual pharmacist views Corporate view prevailsCorporate view prevails
County operated pharmaciesCounty operated pharmacies Hospital-based outpatient pharmacy Hospital-based outpatient pharmacy
(methadone dispensing)(methadone dispensing) Mental health clinic pharmacy Mental health clinic pharmacy
(buprenorphine dispensing)(buprenorphine dispensing)
55
Basic Program Components
All pharmacists involved in the program All pharmacists involved in the program undergo extensive training provided by the undergo extensive training provided by the California Society of Addiction MedicineCalifornia Society of Addiction Medicine
Central database with pertinent client Central database with pertinent client demographic and clinical informationdemographic and clinical information Pharmacists record observed and take Pharmacists record observed and take
home dosing in databasehome dosing in database Communication and clinical data sharing Communication and clinical data sharing
through “SOAP” notes formatthrough “SOAP” notes format
56
Basic Program Components
Program licensure allows exemption from Program licensure allows exemption from Board of Pharmacy prescription Board of Pharmacy prescription requirementsrequirements
““On-call” OBOT program staff to assist with On-call” OBOT program staff to assist with problemsproblems
Physical modifications were made to Physical modifications were made to enhance security and dosing area privacyenhance security and dosing area privacy
Program uses methadone tablets (vs. liquid Program uses methadone tablets (vs. liquid or diskette), or Suboxoneor diskette), or SuboxoneR R
57
Observations, 1 year later
Establishing dosing “appointments” works!Establishing dosing “appointments” works! Estimate of pharmacist time needed for Estimate of pharmacist time needed for
each observed dosing/take home each observed dosing/take home dispensing (5 minutes) too lowdispensing (5 minutes) too low
Regulatory agencies - e.g. DEA, state NTP Regulatory agencies - e.g. DEA, state NTP licensing agency - complimentary of licensing agency - complimentary of pharmacist record keeping, security, and pharmacist record keeping, security, and professional services provided to clientsprofessional services provided to clients
58
more observations…...
Rapport between pharmacist and client Rapport between pharmacist and client quickly and easily establishedquickly and easily established
Pharmacists enjoy client interaction and Pharmacists enjoy client interaction and expanded responsibilities expanded responsibilities
Pharmacists initially reluctant to Pharmacists initially reluctant to “volunteer”, later filed labor grievance to be “volunteer”, later filed labor grievance to be allowed to participateallowed to participate
Clients prefer dosing and receiving take Clients prefer dosing and receiving take home doses in a pharmacy settinghome doses in a pharmacy setting
59
Lessons Learned
Listen to the “experts” - especially those Listen to the “experts” - especially those who actually do the workwho actually do the work
Local buy-in may not be enough, engage Local buy-in may not be enough, engage corporate decision makers if possiblecorporate decision makers if possible
Initial concerns about major legal and Initial concerns about major legal and regulatory obstacles did not materializeregulatory obstacles did not materialize
Flexibility, open-mindedness, and patience Flexibility, open-mindedness, and patience are required traits for anyone involved in a are required traits for anyone involved in a pilot programpilot program
60
Questions?
Sharon Kotabe, PharmDSharon Kotabe, PharmD(415) 206-2325(415) 206-2325